Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge.

Abstract

Effective strategies for preventing human immunodeficiency virus infection are urgently needed, but recent failures in key clinical trials of vaccines and microbicides highlight the need for new approaches validated in relevant animal models. Here, we show that 2 new chemokine (C-C motif) receptor 5 inhibitors, 5P12-RANTES (regulated on activation, normal T cell expressed and secreted) and 6P4-RANTES, fully protect against infection in the rhesus vaginal challenge model. These highly potent molecules, which are amenable to low-cost production, represent promising new additions to the microbicides pipeline.

• Authors: Ronald S Veazey, Binhua Ling, Linda C Green, Erin P Ribka, Jeffrey D Lifson, Michael Piatak Jr, Michael M Lederman, Donald Mosier, Robin Offord, Oliver Hartley
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 199 Issue 10 Pg. 1525-7 (May 15 2009) ISSN: 0022-1899 [Print] United States
• PMID: 19331577 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Chemokine CCL5
• Chemokines
• RANTES, N(alpha)-(n-nonanoyl)-desSer(1)-(thioproline(2),cyclohexylglycine(3))-
• RNA, Viral
• Recombinant Proteins

Topics

• Administration, Topical
• Animals
• Chemokine CCL5 (administration & dosage, therapeutic use)
• Chemokines (administration & dosage, genetics, therapeutic use)
• Female
• Macaca
• RNA, Viral (blood, genetics)
• Recombinant Proteins (administration & dosage, therapeutic use)
• Reverse Transcriptase Polymerase Chain Reaction
• Simian Acquired Immunodeficiency Syndrome (prevention & control)
• Vagina (virology)
• Viral Load